# GSK2190915 Moderate to Severe Asthma Study

> **NCT00850642** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2190195 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00850642
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06-26
- **Primary completion:** 2010-06-02
- **Final completion:** 2010-06-02
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00850642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00850642, "GSK2190915 Moderate to Severe Asthma Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00850642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*